CDKN2A and neoplasm: Five of these 6 patients exhibited treatment-associated decreases in tumor CDKN2A methylation, yet only 1 showed increased tumor p16 expression by IHC (Table 4), indicating a potential discrepancy between the changes in transcriptional versus translational level regulation of tumor p16 expression at the examined timepoints.